Sotagliflozin for Preventing Readmission for Heart Failure (SOLOIST-WHF)
The investigators of a recent randomized trial examined the efficacy of sotagliflozin (a newer combined SGLT2/SGLT1 inhibitor) to prevent rehospitalization in people with diabetes discharged after acute heart failure exacerbations.